AbbVie (NYSE: ABBV) reported Q4 EPS of $2.92, $0.06 better than the analyst estimate of $2.86. Revenue for the quarter came in at $13.86 billion versus the consensus estimate of $13.73 billion.

GUIDANCE:

AbbVie sees FY2021 EPS of $12.32-$12.52, versus the consensus of $12.18.

For earnings history and earnings-related data on AbbVie (ABBV) click here.